The trial involves 54 patients in Switzerland and France, with completion anticipated in December 2029. The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized ...
1d
Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess â„¢) for frown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback